March 21st, 2022 (Earnings Report) Dear Reader, We just identified several healthtech stocks that are expected to release earnings this week. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Fortress Biotech
Symbol: FBIO
Recent Price: $1.48
Average Analyst Price Target: $11.33 (665.54%)
Market Cap: $147.45M
Last Year's EPS: -$0.07
Consensus EPS Forecast: $0.08
Expected Earnings Date: Mar 20 2022
Recent Analyst Action: Jason Kolbert, analyst at Dawson James, reiterates coverage on Fortress Biotech (FBIO) in the Healthcare sector with a Buy rating and a price target of $ 16 (1 month ago).
TipRanks.com also reports that Fortress Biotech currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $11.33 . The target pricing ranges from a high forecast of $16.00 down to a low forecast of $8.00. Fortress Biotech (FBIO)’s last closing price was $1.48 which would put the average price target at 665.54% upside.Here are 3rd party ratings for FBIO:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 37% (158 out of 252)
--------------------------------------------------------------------------
Marinus
Symbol: MRNS
Recent Price: $10
Average Analyst Price Target: $27.33 (173.30%)
Market Cap: $367.66M
Last Year's EPS: -$0.55
Consensus EPS Forecast: -$0.76
Expected Earnings Date: Mar 20 2022
Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on Marinus (MRNS) in the Healthcare sector with a Buy rating and a price target of $ 38 (12 hours ago).
TipRanks.com also reports that Marinus currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $27.33 . The target pricing ranges from a high forecast of $38.00 down to a low forecast of $17.00. Marinus (MRNS)’s last closing price was $10 which would put the average price target at 173.30% upside.Here are 3rd party ratings for MRNS:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
Cincor Pharma
Symbol: CINC
Recent Price: $19.78
Average Analyst Price Target: $29.00 (46.61%)
Market Cap: $722.35M
Last Year's EPS: -$0.16
Consensus EPS Forecast: -$1.56
Expected Earnings Date: Mar 21 2022
Recent Analyst Action: Jeffrey Hung, analyst at Morgan Stanley, reiterates coverage on Cincor Pharma (CINC) in the Healthcare sector with a Buy rating and a price target of $ 27 (1 month ago).
TipRanks.com also reports that Cincor Pharma currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.00 . The target pricing ranges from a high forecast of $30.00 down to a low forecast of $27.00. Cincor Pharma (CINC)’s last closing price was $19.78 which would put the average price target at 46.61% upside.Here are 3rd party ratings for CINC:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Hold, Bottom 37% (158 out of 252)
--------------------------------------------------------------------------
Aptinyx
Symbol: APTX
Recent Price: $3.09
Average Analyst Price Target: $8.00 (158.90%)
Market Cap: $209.24M
Last Year's EPS: -$0.2
Consensus EPS Forecast: -$0.35
Expected Earnings Date: Mar 22 2022
Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on Aptinyx (APTX) in the Healthcare sector with a Buy rating and a price target of $ 8 (2 weeks ago).
TipRanks.com also reports that Aptinyx currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.00 . The target pricing ranges from a high forecast of $8.00 down to a low forecast of $8.00. Aptinyx (APTX)’s last closing price was $3.09 which would put the average price target at 158.90% upside.Here are 3rd party ratings for APTX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Bottom 37% (158 out of 252)
--------------------------------------------------------------------------
Nucana
Symbol: NCNA
Recent Price: $1.03
Average Analyst Price Target: $13.50 (1210.68%)
Market Cap: $53.75M
Last Year's EPS: >-$0.01
Consensus EPS Forecast: >-$0.01
Expected Earnings Date: Mar 22 2022
Recent Analyst Action: Leland Gershell, analyst at Oppenheimer, reiterates coverage on Nucana (NCNA) in the Healthcare sector with a Buy rating and a price target of $ 5 (1 week ago).
TipRanks.com also reports that Nucana currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $13.50 . The target pricing ranges from a high forecast of $22.00 down to a low forecast of $5.00. Nucana (NCNA)’s last closing price was $1.03 which would put the average price target at 1210.68% upside.Here are 3rd party ratings for NCNA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 37% (158 out of 252)
--------------------------------------------------------------------------
PDS Biotechnology
Symbol: PDSB
Recent Price: $6.65
Average Analyst Price Target: $18.50 (178.20%)
Market Cap: $189.11M
Last Year's EPS: -$0.18
Consensus EPS Forecast: -$0.24
Expected Earnings Date: Mar 22 2022
Recent Analyst Action: Robert LeBoyer, analyst at Noble Financial, reiterates coverage on PDS Biotechnology (PDSB) in the Healthcare sector with a Buy rating and a price target of $ 22 (5 days ago).
TipRanks.com also reports that PDS Biotechnology currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.50 . The target pricing ranges from a high forecast of $22.00 down to a low forecast of $15.00. PDS Biotechnology (PDSB)’s last closing price was $6.65 which would put the average price target at 178.20% upside.Here are 3rd party ratings for PDSB:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 37% (158 out of 252)
--------------------------------------------------------------------------
Relmada Therapeutics
Symbol: RLMD
Recent Price: $24.08
Average Analyst Price Target: $62.50 (159.55%)
Market Cap: $667.64M
Last Year's EPS: -$1.28
Consensus EPS Forecast: -$1.83
Expected Earnings Date: Mar 22 2022
Recent Analyst Action: Vamil Divan, analyst at Mizuho Securities, reiterates coverage on Relmada Therapeutics (RLMD) in the Healthcare sector with a Buy rating and a price target of $ 50 (1 week ago).
TipRanks.com also reports that Relmada Therapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $62.50 . The target pricing ranges from a high forecast of $75.00 down to a low forecast of $50.00. Relmada Therapeutics (RLMD)’s last closing price was $24.08 which would put the average price target at 159.55% upside.Here are 3rd party ratings for RLMD:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Sell, Bottom 36% (162 out of 252)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com